Drug Trial Radar · NCT04059913
Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: May 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
318
Actual
Start
Jun 11, 2019
Primary completion
Nov 19, 2021
Study completion Dec 17, 2021
Sponsor
- Lead sponsor
- Kyntra BioIndustry
- Sponsor type
- Industry
- First posted
- Aug 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, multi-center study in dialysis chronic kidney disease (CKD) participants to evaluate the efficacy and relative safety of different dosing regimens of roxadustat over a 36-week treatment period. There are 3 study periods: * Screening Period (up to 4 weeks) * Treatment Period (36 weeks) Part 1: Correction/Conversion Period (Weeks 1-20) Part 2: Hemoglobin (Hb) Maintenance Period (Weeks 21-36) * Follow-up Period (4 weeks)
Conditions
- CKD Anemia in Dialysis Participants
Interventions
RoxadustatDrug
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (ESA Naïve): Percentage of Participants who Achieved Hb ≥110 g/L in the First 20 WeeksTime frame: Weeks 1 to 20
- Part 1 (ESA Treated): Percentage of Participants who Achieved Mean Hb ≥100 g/L Averaged Over Weeks 17 to 21 VisitsTime frame: Weeks 17 to 21
- Part 2: Mean Hb Value Averaged Over Weeks 33 to 37 VisitsTime frame: Weeks 33 to 37
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site
Beijing, China
Investigational Site
Beijing, China
Investigational Site
Beijing, China
Investigational Site
Shanghai, China
Investigational Site
Tianjin, China
Investigational Site
Hefei, Anhui, China
Investigational Site
Lanzhou, Gansu, China
Investigational Site
Guangzhou, Guangdong, China
Investigational Site
Shenzhen, Guangdong, China
Investigational Site
Nanning, Guangxi, China
Investigational Site
Zhengzhou, Henan, China
Investigational Site
Wuhan, Hubei, China
Investigational Site
Changsha, Hunan, China
Investigational Site
Baotou, Inner Mongolia, China
Investigational Site
Nanjing, Jiangsu, China
Investigational Site
Nanchang, Jiangxi, China
Investigational Site
Changchun, Jilin, China
Investigational Site
Shenyang, Liaoning, China
Investigational Site
Shenyang, Liaoning, China
Investigational Site
Taiyuan, Shanxi, China
Investigational Site
Xi’an, Shanxi, China
Investigational Site
Xi’an, Shanxi, China
Investigational Site
Chengdu, Sichuan, China
Investigational Site
Chengdu, Sichuan, China
Investigational Site
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.